


Measles and rubella elimination country profile


Azerbaijan

Measles elimination status




Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrv

Rubella elimination status



Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrv

Measles and rubella surveillance



Source: WHO/UNICEF Joint Reporting Form on Immunization, 2017

Demographic information, 2017

Total population	9 827 589
< 1 year old	171 548
< 5 years old	884 695

Source: World Population Prospects: The 2017 Revision, New York, United Nations


Measles and rubella immunization schedule, 2017

	Vaccine	Schedule	Year of introduction	
MCV1	MMR	12 months	MCV2	2001
MCV2	MMR	6 years	RCV	2003
Measles vaccination in school				No

Source: Immunization schedule, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/)

MMR = measles-mumps-rubella vaccine; MCV1 = first dose measles-containing vaccine; MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccine

Measles and rubella cases and immunization coverage, 2008–2017




Source: Disease incidence and immunization coverage (WUENIC), WHO, Data and Statistics, Immunization Monitoring and Surveillance

(http://www.who.int/immunization/monitoring_surveillance/data/en/)


MCV1 = first dose of measles-containing vaccine
MCV2 = second dose of measles-containing vaccine

Definition used for an outbreak



Source: Measles and rubella elimination Annual Status Update report, 2017

Confirmed measles cases by month of onset, 2013-2017



Source: CISD 2017



Measles and rubella elimination country profile

Azerbaijan

Measles incidence, epidemiologic and virologic characteristics, 2013-2017

	Suspected measles cases	Confirmed measles cases				Discarded as non-measles	Measles incidence	Genotypes detected
		Laboratory	Epi-linked	Clinically	Total			
2013	808	161	3	0	164	644	17.4	D4
2014	75	0	0	0	0	75	0	NA
2015	111	0	0	0	0	111	0	NA
2016	111	0	0	0	0	111	0	NA
2017	88	0	0	0	0	88	0	NA

Source: Measles and rubella elimination Annual Status Update report, 2013-2017
Incidence calculated per 1 million population
ND = Data not available; NA= Not applicable

Rubella incidence, epidemiologic and virologic characteristics, 2013-2017

	Suspected rubella cases	Confirmed rubella cases				Discarded as non-rubella	Rubella incidence	Genotypes detected
		Laboratory	Epi-linked	Clinically	Total			
2013	38	0	0	0	0	38	0	NA
2014	31	0	0	0	0	31	0	NA
2015	43	0	0	0	0	43	0	NA
2016	64	0	0	0	0	64	0	NA
2017	53	0	0	0	0	53	0	NA

Source: Measles and rubella elimination Annual Status Update report, 2013-2017
Incidence calculated per 1 million population
ND = Data not available; NA= Not applicable

RVC comments, based on 2017 reporting

The Regional Verification Commission for Measles and Rubella Elimination (RVC) concluded that endemic transmission of both measles and rubella remained interrupted in Azerbaijan in 2017 and confirmed that measles and rubella elimination has been sustained. Surveillance performance and sensitivity need to be strengthened and better documented.

Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrv

Surveillance performance indicators and targets

- Rate of discarded cases: at least 2 discarded measles or rubella cases per 100 000 population
- % cases with adequate laboratory investigation: $\geq 80\%$
- % origin of infection known: $\geq 80\%$
- Rate of viral detection: $\geq 80\%$

Information on CRS, 2017

No cases reported



Source: Measles and rubella elimination Annual Status Update report, 2017
CRS = congenital rubella syndrome

Measles surveillance and laboratory performance indicators, 2013-2017

	Discarded non-measles rate	% 1st sub-national unit with ≥ 2 discarded cases	% cases with adequate laboratory investigation	% origin of infection known	# specimen tested for measles	% positive for measles	Rate of viral detection	% WHO and proficient labs
2013	7.4	70%	99%	81.1%	ND	ND	ND	ND
2014	1.0	38%	100%	0%	99	0%	0	ND
2015	1.2	45.3%	100%	0%	111	0%	0	100%
2016	1.1	54.7%	100%	0%	175	0%	0	100%
2017	59.4%	ND	90%	100%	88	0%	0	100%

Source: ASU 2013-2017
ND = Data not available; NA= Not applicable
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

Rubella surveillance and laboratory performance indicators, 2013-2017

	Discarded non-rubella rate	% 1st sub-national unit with ≥ 2 discarded cases	% cases with adequate laboratory investigation	% origin of infection known	# specimen tested for rubella	% positive for rubella	Rate of viral detection	% WHO and proficient labs
2013	0.4	14%	100%	ND	ND	ND	ND	ND
2014	0.4	20.3%	100%	0%	35	0%	0	ND
2015	0.4	31.3%	100%	0%	43	0%	0	100%
2016	0.1	34.4%	100%	0%	202	0%	0	100%
2017	0.5	42.2%	100%	100%	53	0%	0	100%

Source: ASU 2013-2017
ND = Data not available; NA= Not applicable
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory